Clinuvel Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Clinuvel Pharmaceuticals is a dividend paying company with a current yield of 0.42%.
Key information
0.4%
Dividend yield
0.1%
Buyback Yield
| Total Shareholder Yield | 0.6% |
| Future Dividend Yield | 1.0% |
| Dividend Growth | 25.5% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | AU$0.050 |
| Payout ratio | 7% |
Recent dividend and buyback updates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Clinuvel Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CUV) | 0.4% |
| Market Bottom 25% (AU) | 2.6% |
| Market Top 25% (AU) | 6.2% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (CUV) (up to 3 years) | 1.0% |
Notable Dividend: CUV's dividend (0.42%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.65%).
High Dividend: CUV's dividend (0.42%) is low compared to the top 25% of dividend payers in the Australian market (6.18%).
Earnings Payout to Shareholders
Earnings Coverage: CUV is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: CUV is not paying a notable dividend for the Australian market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 22:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| David Stanton | Jefferies LLC |